Hubungan Paritas Dengan Kejadian Positif HPV DNA Pada Perempuan Di Sumatera Selatan Tahun 2024

Tri Sisca Sisilia; Rini Mutahar; Iche Andriyani Liberty

doi:10.31004/koloni.v5i3.1419

Authors

Tri Sisca Sisilia Universitas Sriwijaya
Rini Mutahar Universitas Sriwijaya
Iche Andriyani Liberty sisca9791@gmail.com

DOI:

https://doi.org/10.31004/koloni.v5i3.1419

Keywords:

HPV DNA, Parity, Reproductive factors, women, South Sumatra

Abstract

Human Papillomavirus (HPV) infection is a major factor in the development of cervical cancer. Parity is one of the reproductive factors suspected to be associated with HPV infection, although previous studies have shown inconsistent findings. This study aimed to analyze the association between parity and HPV DNA positivity among women in South Sumatra in 2024. A case-control design was conducted using secondary data from 212 subjects, consisting of 106 HPV DNA-positive cases and 106 HPV DNA-negative controls. Parity was categorized as <3 and ≥3. Data were analyzed using the Chi-square test, Fisher’s Exact Test, and logistic regression. The magnitude of association was expressed as an odds ratio (OR) with a 95% confidence interval (CI). The results showed that 70.28% of subjects had parity <3 and 29.72% had parity ≥3. The proportion of HPV DNA positivity was 53.69% among women with parity <3 and 41.27% among those with parity ≥3. Women with parity ≥3 had 0.606 times the odds of HPV DNA positivity compared with women with parity <3 (OR=0.606; 95% CI: 0.334–1.100; p=0.098). None of the potential confounding variables changed the parity OR by ≥10%. In conclusion, there was no statistically significant association between parity and HPV DNA positivity.

References

Ardekani, A., Sepidarkish, M., Mollalo, A., et al. (2023). Worldwide prevalence of human papillomavirus among pregnant women: A systematic review and meta-analysis. Reviews in Medical Virology, 33(1), e2374. https://doi.org/10.1002/rmv.2374

Ferris, D. G., Brown, D. R., Giuliano, A. R., Myers, E., Joura, E. A., Garland, S. M., et al. (2020). Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Research, 10, 100202.

Gravitt, P. E., & Winer, R. L. (2017). Natural history of HPV infection across the lifespan: Role of viral latency. Viruses, 9(10), 267. https://doi.org/10.3390/v9100267

Jensen, K. E., Schmiedel, S., Norrild, B., Frederiksen, K., Iftner, T., & Kjær, S. K. (2013). Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: A 13-year follow-up. British Journal of Cancer, 108(1), 234–239. https://doi.org/10.1038/bjc.2012.513

Lee, P. H. (2014). Is a cutoff of 10% appropriate for the change-in-estimate criterion of confounder identification? Journal of Epidemiology, 24(2), 161–167. https://doi.org/10.2188/jea.JE20130062

Malagón, T., Volesky, K. D., Bouten, S., Laprise, C., El-Zein, M., & Franco, E. L. (2020). Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. International Journal of Cancer, 147(10), 2695–2707. https://doi.org/10.1002/ijc.33035

Nahar, Q., Sultana, F., Alam, A., Islam, J. Y., Rahman, M., Khatun, F., et al. (2014). Genital human papillomavirus infection among women in Bangladesh: Findings from a population-based survey. PLoS ONE, 9(10), e107675. https://doi.org/10.1371/journal.pone.0107675

Nielsen, A., Iftner, T., Munk, C., & Kjær, S. K. (2009). Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sexually Transmitted Diseases, 36(10), 609–615. https://doi.org/10.1097/OLQ.0b013e3181a96d0e

Roset Bahmanyar, E., Paavonen, J., Naud, P., Salmerón, J., Chow, S. N., Apter, D., et al. (2012). Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 127(3), 440–450. https://doi.org/10.1016/j.ygyno.2012.08.033

Wulandari, D., Meidyandra, R. W., & Andrijono. (2023). Genotype profiles of high-risk human papillomavirus in women of reproductive age: A community-based study. PLoS ONE, 18(7), e0287399. https://doi.org/10.1371/journal.pone.0287399

Zhao, M., Zhou, D., Zhang, M., Kang, P., Cui, M., Zhu, L., & Luo, L. (2023). Characteristic of persistent human papillomavirus infection in women worldwide: A meta-analysis. PeerJ, 11, e16247. https://doi.org/10.7717/peerj.16247

World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention (2nd ed.). Geneva: World Health Organization. WHO merekomendasikan HPV DNA sebagai pemeriksaan primer dibandingkan VIA atau sitologi.

World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of mRNA tests for human papillomavirus (HPV). Geneva: World Health Organization.

World Health Organization. (2024). Human papillomavirus and cancer. World Health Organization. WHO Human papillomavirus and cancer

World Health Organization. (2026). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of human papillomavirus (HPV) DNA genotyping. Geneva: World Health Organization.